Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response 1,2. Anti-PD-1 antibodies have shown remarkable promise in treating tumours, including metastatic melanoma 2-4. However, the patient response rate is low 4,5. A better understanding of PD-L1-mediated immune evasion is needed to predict patient response and improve treatment efficacy. Here we report that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface. Stimulation with interferon-γ (IFN-γ) increases the amount of PD-L1 on these vesicles, which suppresses the function of CD8 T cells and facilitates tumour growth. In patients with metastatic melanoma, the level of circulating exosomal PD-L1 positively correlates with that of IFN-γ, and varies during the course of anti-PD-1 therapy. The magnitudes of the increase in circulating exosomal PD-L1 during early stages of treatment, as an indicator of the adaptive response of the tumour cells to T cell reinvigoration, stratifies clinical responders from non-responders. Our study unveils a mechanism by which tumour cells systemically suppress the immune system, and provides a rationale for the application of exosomal PD-L1 as a predictor for anti-PD-1 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Chen et al., 2018
In the citing paper
“In cancer patients undergoing anti-PD-1 treatment, pre-treatment levels of circulating exosomal PD-L1 were higher in those who did not benefit from the treatment, reflecting the role of exosomal PD-L1 in tumor immunity and its potential association with T cell exhaustion (Chen et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Chen et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationMelanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
“PD-L1 on melanoma-derived exosomes suppresses CD8 T cell antitumor function in vivo (82), and cancer cell–derived exosomes block dendritic cell maturation and migration in a PD-L1–dependent manner (83).”
BackgroundThe evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Pegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Metadata
- Authors
- Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., Liu, S., Yang, R., Lu, Y., Dong, L., McGettigan, S., Somasundaram, R., Radhakrishnan, R., Mills, G., Lu, Y., Kim, J., Chen, Y. H., Dong, H., Zhao, Y., Karakousis, G. C., Mitchell, T. C., Schuchter, L. M., Herlyn, M., Wherry, E. J., Xu, X., & Guo, W.
- Affiliations
- University of Pennsylvania (US)
- Wuhan University (CN)
- The Wistar Institute (US)
- Abramson Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- Corresponding author
- Xu, Wei
- Xu, Xiaowei
- Guo, Wei
- ORCID
- Chen, Gang
- Huang, Alexander C.
- Zhang, Wei
- Zhang, Gao
- Wu, Min
- Xu, Wei
- Yang, Jiegang
- Wang, Beike
- Zhong, Wenqun
- Wu, Bin
- Xiong, Xuepeng
- Liu, Xiaoming
- Guan, Lei
- Liu, Shujing
- Yang, Ruifeng
- Lu, Youtao
- Dong, Liyun
- McGettigan, Suzanne
- Somasundaram, Rajasekharan
- Radhakrishnan, Ravi
- Mills, Gordon
- Lu, Yiling
- Kim, Junhyong
- Chen, Youhai H.
- Dong, Haidong
- Karakousis, Giorgos C.
- Mitchell, Tara C.
- Schuchter, Lynn M.
- Herlyn, Meenhard
- Wherry, E. John
- Xu, Xiaowei
- Guo, Wei
- Venue
- Nature
- Published
- 2018-08
- Volume
- 560
- Issue
- 7718
- Pages
- 382-386
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6095740
- OpenAlex
- W2887249435
- Cited by
- 2,813
- References
- 33
- Citations by year
- 2026: 258 · 2025: 325 · 2024: 422 · 2023: 382 · 2022: 398 · 2021: 416 · 2020: 365 · 2019: 212 · 2018: 30
- FWCI
- 96.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA047159, P01CA114046, U54CA193417, P01CA025874, P50CA174523, T32CA009615, P30CA010815)
- National Institute of General Medical Sciences (R01GM111128, R01GM085146)
- National Institute of Allergy and Infectious Diseases (R01AI105343, U19AI117950, U19AI082630, P01AI108545)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- exosomal PD-L1, exosomes, metastatic melanoma, immune checkpoint evasion, PD-1/PD-L1 interaction, anti-PD-1 therapy, interferon-gamma, CD8+ T cell suppression, tumor immune evasion, predictive biomarkers, treatment response stratification, circulating exosomes
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Female, Humans, Immune Tolerance, Interferon-gamma, Melanoma, Mice, Nude, Neoplasm Metastasis, Prognosis, Case-Control Studies, CD8-Positive T-Lymphocytes, Disease Progression, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Exosomes, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. https://app.cochat.ai/papers/10.1038/s41586-018-0392-8
- The paper
- Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., . . . Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. https://doi.org/10.1038/s41586-018-0392-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.